drugset
drugset / Trial / NCT05723692

A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers

NCT05723692 ↗

Phase 1 Completed 56 enrolled AltruBio Inc. ICON plc · collab
RandomizedSequentialDouble-blindTreatment

Summary

This study with ALTB-268 will determine the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of ALTB-268 in healthy volunteers.

Timeline

Start
2023-01-17
Primary completion
2023-10-27
Completion
2023-10-27

Drugs

EvaluationDrugModalityDoseRoute
Subject ALTB-268 Monoclonal antibody — Subcutaneous

Indications

No indication recorded.